Pushing the network away from fusion using the OPA1 inhibitor MYLS22 reduces mitochondrial membrane potential, perturbs MM-MSC glycolysis/OXPHOS coupling, and lowers mitochondrial ROS compared to the normal donor MSCs, weakening their pro-tumor support. The gene discussed is OPA1; the disease is neoplasm.